What ' s Going On Avidity Biosciences Stock Today?

Monday, Avidity Biosciences Inc RNA revealed new long-term AOC 1001 data from the MARINA open-label extension (MARINA-OLE) trial showing reversal of disease progression in myotonic dystrophy type 1 (DM1) patients across multiple endpoints compared to END-DM1 natural history data. These are the…#aoc1001 #qmt #avidity #deldesiran #myotonia #dm1activ #rna
Source: Reuters: Health - Category: Consumer Health News Source Type: news